Efficacy of an escalating dose regimen of pegylated interferon α-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

Transplant International

Volumn 20, Issue 7, 2007, Pages 583-590

  Zimmermann, Tim ^a   Böcher, Wulf O ^a   Biesterfeld, Stefan ^a   Zimmermann, Anca ^a   Kanzler, Stefan ^a   Greif Higer, Gertrud ^a   Barreiros, Ana Paula ^a   Sprinzl, Martin F ^a   Wörns, Marcus A ^a   Lohse, Ansgar W ^a,b   Mönch, Christian ^a   Otto, Gerd ^a   Galle, Peter R ^a   Schuchmann, Marcus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Hepatitis C; Liver transplantation; Reinfection; Treatment

Indexed keywords

CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; REINFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 34249897781     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00481.x     Document Type: Article

References (33)

1. Berenguer M, Lopez-Labrador X, Wright T. Hepatitis C and liver transplantation. J Hepatol 2001 35 : 666.
2. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus infected recipients. Liver Transpl 2003 11 : 28.
3. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002 35 : 680.
4. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996 23 : 971.
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M. HCV related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 32 : 673.
6. Berenguer M, Prieto M, Rayon JM, Mora J, Pasor M, Ortiz V. Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000 32 : 852.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 12 : 889.
8. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999 29 : 250.
9. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 7 : 442.
10. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002 8 : 40.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales F. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975.
12. Samuel D, Feray C. Recurrence of hepatitis C virus after liver transplantation. J Hepatol 1999 31 (Suppl. 1 217.
13. Di Martino V, Saurini F, Samuel D, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997 26 : 1343.
14. Pelletier SJ, Raymond DP, Crabtree TD, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000 32 : 418.
15. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998 352 : 1426.
16. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Heptology 1995 22 : 1084.
17. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994 330 : 1160.
18. Gadano AC, Mosnier JF, Durand F, et al. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995 59 : 1627.
19. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 42 : 255.
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696.
21. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999 117 : 619.
22. Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995 27 : 1222.
23. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 2005 79 : 261.
24. Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003 124 : 642.
25. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (α 2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005 43 : 53.
26. Rodrigues-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C after liver transplantation with combination of pegylated interferon alpha 2b and ribavirin: an open label series. Transplantation 2004 77 : 190.
27. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004 40 : 669.
28. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with reccurent hepatitis C after liver transplantation with peginterferon alfa-2b puls ribavirin. Transplantation 2006 82 : 43.
29. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001 345 : 1452.
30. Lavezzo B, Franchello A, Smeddile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve months course of interferon alpha 2b with ribavirin. J Hepatol 2002 37 : 247.
31. Ghalib R, Levin C, Stribling R. Treatment of recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2b plus ribavirin. Preliminary analysis [Abstract]. Gastroenterology 2003 124 : A-694.
32. Fernández I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006 12 : 1805.
33. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005 41 : 289.